Corporate ActionAug 5, 2026, 05:34 PM
Veraxa Biotech Details Recent Capital Raises, Business Combination
AI Summary
Veraxa Biotech Holding AG detailed a series of capital actions and corporate restructuring events in its F-1 filing. Key events include the consummation of a business combination on June 10, 2026, which resulted in the issuance of 130,000,128 new PubCo Ordinary Shares. The company also secured $27.5 million in a senior secured note and a $27.5 million warrant through High Trail Financing, and entered into a purchase agreement with Lincoln Park for up to $50.0 million in share purchases. Additionally, the filing disclosed the issuance of 3,500,000 shares to Cantor Fitzgerald & Co. for a fee modification and various private offerings from 2023-2025 totaling over CHF 29.9 million.
Key Highlights
- Completed Business Combination on June 10, 2026, issuing 130,000,128 new PubCo shares.
- Secured $27.5 million senior note and $27.5 million warrant from High Trail Financing.
- Entered agreement with Lincoln Park for up to $50.0 million share purchases over 24 months.
- Issued 3,500,000 Ordinary Shares to Cantor Fitzgerald & Co. for fee modification.
- Issued 7,665,000 Private Warrants at $1.00 each, generating $7.665 million.
- Completed various private offerings from 2023-2025 totaling over CHF 29.9 million.
- Issued 487,942 Employee Stock (ESOP) shares to Directors in 2024-2025.
Price Impact
More from VRXA